Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

846 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Passive antibody therapy for infectious diseases.
Casadevall A, Dadachova E, Pirofski LA. Casadevall A, et al. Nat Rev Microbiol. 2004 Sep;2(9):695-703. doi: 10.1038/nrmicro974. Nat Rev Microbiol. 2004. PMID: 15372080 Review.
Antibody-based therapies are currently undergoing a renaissance. After being developed and then largely abandoned in the twentieth century, many antibody preparations are now in clinical use. ...
Antibody-based therapies are currently undergoing a renaissance. After being developed and then largely abandoned in the twentieth ce …
Extensive allelic variation in Cryptococcus neoformans.
Casadevall A, Freundlich LF, Marsh L, Scharff MD. Casadevall A, et al. J Clin Microbiol. 1992 May;30(5):1080-4. doi: 10.1128/JCM.30.5.1080-1084.1992. J Clin Microbiol. 1992. PMID: 1349897 Free PMC article.
Protective murine monoclonal antibodies to Cryptococcus neoformans.
Mukherjee J, Scharff MD, Casadevall A. Mukherjee J, et al. Among authors: casadevall a. Infect Immun. 1992 Nov;60(11):4534-41. doi: 10.1128/IAI.60.11.4534-4541.1992. Infect Immun. 1992. PMID: 1398966 Free PMC article.
The protection model used A/J and BALB/c mice infected intraperitoneally with 10(8) cryptococci. The MAbs were administered either immediately preceding or, in one experiment, 24 to 48 h prior to infection. ...Three IgM MAbs, each of which recognized a distinct epit …
The protection model used A/J and BALB/c mice infected intraperitoneally with 10(8) cryptococci. The MAbs were administered either im …
Monoclonal antibody based ELISAs for cryptococcal polysaccharide.
Casadevall A, Mukherjee J, Scharff MD. Casadevall A, et al. J Immunol Methods. 1992 Sep 18;154(1):27-35. doi: 10.1016/0022-1759(92)90209-c. J Immunol Methods. 1992. PMID: 1401941
Mouse monoclonal antibody (MAb)-based enzyme-linked immunosorbent assays (ELISAs) have been developed to detect Cryptococcus neoformans capsular polysaccharide from the four serotypes A, B, C and D. ...The presence of polysaccharide is detected using MAbs of a diffe …
Mouse monoclonal antibody (MAb)-based enzyme-linked immunosorbent assays (ELISAs) have been developed to detect Cryptococcus neoformans caps …
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
Casadevall A, Scharff MD. Casadevall A, et al. J Exp Med. 1991 Jul 1;174(1):151-60. doi: 10.1084/jem.174.1.151. J Exp Med. 1991. PMID: 1676047 Free PMC article.
Cryptococcus neoformans is a ubiquitous fungus that can cause serious infections in humans. The fungus has a polysaccharide (C. neoformans capsular polysaccharide; CNPS) capsule that contributes to its pathogenicity and can elicit an antibody response. Nevertheless, …
Cryptococcus neoformans is a ubiquitous fungus that can cause serious infections in humans. The fungus has a polysaccharide (C …
Current state of the hybridoma technology.
Pirofski L, Casadevall A, Rodriguez L, Zuckier LS, Scharff MD. Pirofski L, et al. Among authors: casadevall a. J Clin Immunol. 1990 Nov;10(6 Suppl):5S-12S; discussion 12S-14S. doi: 10.1007/BF00918686. J Clin Immunol. 1990. PMID: 2081790 Review.
The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human disease. ...The potential to renew indefinitely a particular antibody surmounted many of the technical and regulatory problems that made …
The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human dis …
Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J, Feldmesser M, Scharff MD, Casadevall A. Mukherjee J, et al. Among authors: casadevall a. Antimicrob Agents Chemother. 1995 Jul;39(7):1398-405. doi: 10.1128/aac.39.7.1398. Antimicrob Agents Chemother. 1995. PMID: 7492075 Free PMC article.
Fluconazole (FLU) is a triazole antibiotic which is effective against C. neoformans. The efficacy of MAb 2H1 in combination with FLU was studied in vitro with the murine macrophage-like cell line J7741.16 and in vivo in mice infected intravenously. ...For the in vivo exper …
Fluconazole (FLU) is a triazole antibiotic which is effective against C. neoformans. The efficacy of MAb 2H1 in combination with FLU …
Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody.
Lee SC, Kress Y, Dickson DW, Casadevall A. Lee SC, et al. Among authors: casadevall a. J Neuroimmunol. 1995 Oct;62(1):43-52. doi: 10.1016/0165-5728(95)00097-l. J Neuroimmunol. 1995. PMID: 7499491
Addition of the murine monoclonal antibody (mAb) 2H1 (IgG1, kappa) to the capsular glucuronoxylomannan (GXM) produced a dose-dependent enhancement of C. neoformans phagocytosis by microglia. ...Enhancement of microglial activity in vivo by opsonins may be a useful t …
Addition of the murine monoclonal antibody (mAb) 2H1 (IgG1, kappa) to the capsular glucuronoxylomannan (GXM) produced a dose-dependen …
Return to the past: the case for antibody-based therapies in infectious diseases.
Casadevall A, Scharff MD. Casadevall A, et al. Clin Infect Dis. 1995 Jul;21(1):150-61. doi: 10.1093/clinids/21.1.150. Clin Infect Dis. 1995. PMID: 7578724 Free PMC article. Review.
Antibody immunity and invasive fungal infections.
Casadevall A. Casadevall A. Infect Immun. 1995 Nov;63(11):4211-8. doi: 10.1128/IAI.63.11.4211-4218.1995. Infect Immun. 1995. PMID: 7591049 Free PMC article. Review. No abstract available.
846 results
Jump to page
Feedback